Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Christine Zurawski"'
Autor:
Steven Shaefer Spires, Elizabeth Dodds Ashley, Travis M Jones, April Dyer, Alicia Nelson, Deverick J Anderson, Melissa D Johnson, Christine Zurawski, Todd Parker, Rebekah W Moehring, Moiz Master, Melina Diaz, Oida Corry-Wiggins, Angelina Davis
Publikováno v:
Open Forum Infectious Diseases. 9
Background Benchmarking AU is important to identify opportunities and allocate resources within a health system. Patient level factors such as infection diagnosis codes further refine risk adjustments but have not been more widely adopted because of
Autor:
Kristen Andreatta, Javier Szwarcberg, Damian J McColl, Jan van Lunzen, William J. Towner, Raji Swamy, Adriano Lazzarin, Christine Zurawski, Thai Nguyen, Mark T. Nelson, Edwin DeJesus, Jose R. Arribas, Manuela Doroana
Publikováno v:
HIV Clinical Trials. 18:118-125
Antiretroviral therapy (ART) simplification to a single-tablet regimen can benefit HIV-1-infected, virologically suppressed, individuals on ART composed of multiple pills.We assessed long-term efficacy and safety of switching to co-formulated elviteg
Autor:
Elizabeth Dodds Ashley, Christine Zurawski, Kimberly Mann, Daniel J. Sexton, Michael E Yarrington, Jesse Couk, Rebekah W. Moehring, Angelina Davis, Julia Coluccio, Todd Parker
Publikováno v:
Open Forum Infectious Diseases
Background Distinguishing active C. difficile infection (CDI) from asymptomatic colonization remains a significant challenge. A multi-step testing algorithm can improve the diagnostic accuracy of CDI and associated antibacterial prescribing. This stu
Autor:
Angelina Davis, Christine Zurawski, Rebekah W. Moehring, Daniel J. Sexton, Todd Parker, Jesse Couk
Publikováno v:
Open Forum Infectious Diseases. 3
Autor:
Michael F. Para, Clifford Kinder, David Shamblaw, Jason Flamm, Christine Zurawski, Martin S. Rhee, Thanes Vanig, Michael Wohlfeiler, Benjamin Young, Joseph Gathe, Sorana Segal-Maurer, Bruce Rashbaum
Publikováno v:
Open Forum Infectious Diseases
Background Black adults are disproportionately affected by HIV. Methods We conducted a 96-week subgroup analysis by race (Black vs. non-Black) for efficacy (pre-specified) and safety (post-hoc) from a randomized, double blind, active-controlled study
Autor:
Roy M, Gulick, Jacob, Lalezari, James, Goodrich, Nathan, Clumeck, Edwin, DeJesus, Andrzej, Horban, Jeffrey, Nadler, Bonaventura, Clotet, Anders, Karlsson, Michael, Wohlfeiler, John B, Montana, Mary, McHale, John, Sullivan, Caroline, Ridgway, Steve, Felstead, Michael W, Dunne, Elna, van der Ryst, Howard, Mayer, Christine, Zurawski
Publikováno v:
New England journal of medicine, 359(14), 1429-1441. Massachussetts Medical Society
BACKGROUND: CC chemokine receptor 5 antagonists are a new class of antiretroviral agents. METHODS: We conducted two double-blind, placebo-controlled, phase 3 studies--Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced
Autor:
Craig Dietz, Giuliano Rizzardini, Christine Zurawski, Keikawus Arastéh, Dennis Pontani, Will Garner, Thai Nguyen, Jose R. Arribas
Publikováno v:
Journal of the International AIDS Society
Introduction : Simplification to Stribild (STB) was statistically superior to continuation of a ritonavir-boosted protease inhibitor (PI+RTV) with emtricitabine and tenofovir DF (FTC/TDF) at week (W) 48 in virologically suppressed HIV adults (1). We
Autor:
Ramin Ebrahimi, William Robbins, Christine Zurawski, Thai Nguyen, David Piontkowsky, Anthony Scarsella, Douglas Cunningham, Jason Hindman, David Shamblaw
Publikováno v:
Open Forum Infectious Diseases
© 2014 Gilead Sciences, Inc. All rights reserved. • STRATEGY-PI is an ongoing Phase 3b trial evaluating the safety and efficacy of a regimen simplification strategy: continuation of a multi-tablet ritonavir-boosted protease inhibitor (PI + RTV) wi